Hyderabad (Telangana): Three-year-old Ayaansh Gupta from Hyderabad, suffering from a rare disease Spinal Muscular Atrophy (SMA), has been administered with the world's most expensive medicine 'Zolgensma', after his parents mobilised Rs 16 crore through crowd-funding. Ayaansh, son of Yogesh Gupta and Rupal Gupta, was given Zolgensma on June 9 at Rainbow Children's Hospital, Secunderabad, under the supervision of Dr Ramesh Konanki, Consultant Pediatric Neurologist.
Zolgensma is the world's most expensive drug and is currently not available in India. It is being imported from the USA at a cost of USD 2,125,000 (INR. 16 Crores). Spinal Muscular Atrophy is a progressive neuromuscular disease caused due to defect in the SMN1 gene. The affected children develop muscle weakness involving upper and lower limbs initially, but over time develop breathing difficulty and swallowing difficulty. SMA affects one in 10,000 children generally, and there are nearly 800 children suffering from SMA in India currently, and thrice as many children die before they even reach their second birthday.
Also read:Hyderabad parents take to crowdfunding for son's treatment
Zolgensma is a single dose intravenous injection gene therapy in which the defective SMN1 gene is replaced through an adenoviral vector. Earlier, two children have been given Zolgensma at Rainbow Children's Hospital, Secunderabad, in August 2020 and April 2021, and the medicine was provided by Novartis free of cost, on compassionate grounds. Both these children are recovering quite well and making progress in their physical growth and development. Elaborating details, Dr Ramesh Konanki stated that currently, there are three proven treatments for children suffering from SMA. "They have to be given either of Zolgensma, Spinraza and Risdiplam. Unfortunately, none of these medicines is currently available in India, and all are hugely expensive.
Spinraza and Risdiplam need to be taken life-long, and costs around Rs 40-70 Lakh per year. Hundreds of children affected with SMA do not have access to any of these treatments due to the mammoth costs involved for treatment," Dr Ramesh said. The Consultant Pediatric Neurologist, on behalf of the medical community and the SMA community (CureSMA group), requested Central and state governments to negotiate with respective pharma companies and make these medicines available at an affordable price.